24H Stock Chart & Stats
€3.18
-€0.06(-1.91%)
At close: 4:00 PM EDT
€3.18
-€0.06(-1.91%)
Day’s Range― - ―
52-Week Range€2.19 - €3.80
Previous CloseN/A
Volume0.00
Average Volume (3M)283.00
Market Cap
€318.65M
Enterprise Value€4.01K
Total Cash (Recent Filing)€552.81M
Total Debt (Recent Filing)€1.03B
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 05, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume590
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.38Price Target Upside194.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€40.29M
Bulls Say, Bears Say
Bulls Say
Strong Phase III/confirmatory Clinical DataLarge, statistically significant ConfideS and supportive PAES results materially strengthen the clinical value proposition of imlifidase. Durable efficacy and reduced dialysis dependency improve the case for payer support, label expansion and clinician adoption, underpinning sustainable commercial roll‑out if regulatory approvals follow.
EUR 150M Out‑licensing Deal Strengthens LiquidityThe SERB agreement and EUR 110m upfront meaningfully extend runway and reduce near‑term refinancing pressure. This durable liquidity boost funds U.S. launch readiness, regulatory work, and commercialization investments, lowering solvency risk while management executes market entry and milestone delivery.
U.S. Launch Readiness And Sizable Addressable MarketClear PDUFA timing, experienced commercial hires and focused engagement of the highest‑volume transplant centers provide structural readiness to capture the large CPRA>98% patient pool. A concrete launch plan against a sizable addressable market supports durable revenue opportunity if approval and reimbursement align.
Bears Say
Sharp Revenue Decline And Deep LossesA steep, sustained revenue drop and very large net losses indicate the business lacks current scale to cover fixed costs. Even with attractive product gross margins, persistent top‑line erosion and negative profitability undermine cash generation and increase reliance on external financing, constraining strategic options.
Negative Equity And High Total DebtA negative equity base combined with ~1.03B of debt materially elevates refinancing and solvency risk. Leverage limits flexibility for M&A, partnering or pricing concessions, may trigger lender covenants, and reduces resilience to setbacks in commercialization or regulatory timelines absent sustained profitability or further non‑dilutive funding.
Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating cash flow and free cash flow signal ongoing cash consumption to support operations and launches. Even with the SERB upfront, the company remains dependent on financing until product sales scale, creating dilution or refinancing risk and limiting ability to invest opportunistically or absorb launch setbacks.
24H FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was €2.19 and its highest was €3.80 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is €318.65M.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 95 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -€0.232 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€0.201.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 0.52.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -€0.232 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went up 2.383%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in DE:24H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
24H Stock 12 Month Forecast
Average Price Target
€9.38
▲(194.83% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―